Wojciech P. Polkowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wojciech P. Polkowski has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Andrzej Kurylcio
2 shared publicationsMagdalena Skórzewska
2 shared publications- Robert Sitarz
Department of Normal, Clinical and Imaging Anatomy, Medical University of Lublin, 20-950 Lublin, Poland
2 shared publications - Alexander Knuth
National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Alfredo Garofalo
Reparto di Chirurgia Oncologica, Institutio Nazionale Tumori Regina, Roma 00144, Italia
1 shared publication Andrzej J. Stanisławek
Department of Surgical Oncology, Medical University of Lublin Lublin Poland
1 shared publication
Latest Publications
- Open Access
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Family Medicine & Primary Care Review
- Vol. 4, 473-476
Lipomas – a health condition that cannot be ignored
Background . Lipomas are the most common forms of benign soft tissue tumors. They occur as various-sized lumps that rarely transform into malignant tumors. They form as a result of a focal hypertrophy of adipose cells and are usually located subcutaneously. Generally, they are palpable through...
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Family Medicine & Primary Care Review
- Vol. 4, 473-476
Open AccessLipomas – a health condition that cannot be ignored
Background . Lipomas are the most common forms of benign soft tissue tumors. They occur as various-sized lumps that rarely transform into malignant tumors. They form as a result of a focal hypertrophy of adipose cells and are usually located subcutaneously. Generally, they are palpable through...
- 9 April 2014
- Published by VM Media Group sp. z o.o in Nowotwory. Journal of Oncology
- Vol. 64 (2) , 129-134
Wyniki leczenia chorych na nowotwory złośliwe z przerzutami do wątroby: 8-letnie doświadczenie jednego ośrodka
Introduction. Surgical treatment of liver metastases from solid tumours should be provided by multidisciplinary teams. Aim. The aim of the present study is to analyse results of the combined treatment of patients with different solid tumours and liver metastases by single institution multidisciplinary team for last 8 years. Material and methods. This is a retrospective analysis of 166 patients (84 females and 82 males), aged from 19 to 78 years (mean 58 ± 11.2), treated due to liver metastases from solid tumours in various primary localizations: except neuroendocrine tumours. In every patient, perioperative systemic therapy was evaluated in agreement with current recommendations of the Polish Union of Oncology. Results. In the follow-up time available (median 35 months) 46% of patients died. Liver resections were performed in 107 (65%) patients, including 19 patients in whom resections were supplemented with (RF-)thermoablations of their liver metastases. This was the sole surgical treatment in the 59 (36%) patients. Perioperative mortality was 1.2%. Grade II complications according to the Clavien-Dindo classification were found in 33 (19.8%) patients, whereas grade III and IV complications were treated in 8 (4.8%) patients. One-, 3-, and 5-year survival rates were respectively 78%, 41%, and 37%. Five-year overall survival in patients with colorectal carcinoma after liver resection of metachronous metastases was 48%. We conclude that combined treatment of patients with liver metastases from non-endocrine solid tumours by the multidisciplinary team is safe and effective. A nearly 50% 5-year survival is achievable in a carefully selected group of patients. We also conclude that hepatic resection is an optimal method of surgical treatment of liver metastases. Introduction. Surgical treatment of liver metastases from solid tumours should be provided by multidisciplinary teams. Aim. The aim of the present study is to analyse results of the combined treatment of patients with different solid tumours and liver metastases by single institution multidisciplinary team for last 8 years. Material and methods. This is a retrospective analysis of 166 patients (84 females and 82 males), aged from 19 to 78 years (mean 58 ± 11.2), treated due to liver metastases from solid tumours in various primary localizations: except neuroendocrine tumours. In every patient, perioperative systemic therapy was evaluated in agreement with current recommendations of the Polish Union of Oncology. Results. In the follow-up time available (median 35 months) 46% of patients died. Liver resections were performed in 107 (65%) patients, including 19 patients in whom resections were supplemented with (RF-)thermoablations of their liver metastases. This was the sole surgical treatment in the 59 (36%) patients. Perioperative mortality was 1.2%. Grade II complications according to the Clavien-Dindo classification were found in 33 (19.8%) patients, whereas grade III and IV complications were treated in 8 (4.8%) patients. One-, 3-, and 5-year survival rates were respectively 78%, 41%, and 37%. Five-year overall survival in patients with colorectal carcinoma after liver resection of metachronous metastases was 48%. We conclude that combined treatment of patients with liver metastases from non-endocrine solid tumours by the multidisciplinary team is safe and effective. A nearly 50% 5-year survival is achievable in a carefully selected group of patients. We also conclude that hepatic resection is an optimal method of surgical treatment of liver metastases.
- 9 April 2014
- Published by VM Media Group sp. z o.o in Nowotwory. Journal of Oncology
- Vol. 64 (2) , 129-134
Wyniki leczenia chorych na nowotwory złośliwe z przerzutami do wątroby: 8-letnie doświadczenie jednego ośrodka
Introduction. Surgical treatment of liver metastases from solid tumours should be provided by multidisciplinary teams. Aim. The aim of the present study is to analyse results of the combined treatment of patients with different solid tumours and liver metastases by single institution multidisciplinary team for last 8 years. Material and methods. This is a retrospective analysis of 166 patients (84 females and 82 males), aged from 19 to 78 years (mean 58 ± 11.2), treated due to liver metastases from solid tumours in various primary localizations: except neuroendocrine tumours. In every patient, perioperative systemic therapy was evaluated in agreement with current recommendations of the Polish Union of Oncology. Results. In the follow-up time available (median 35 months) 46% of patients died. Liver resections were performed in 107 (65%) patients, including 19 patients in whom resections were supplemented with (RF-)thermoablations of their liver metastases. This was the sole surgical treatment in the 59 (36%) patients. Perioperative mortality was 1.2%. Grade II complications according to the Clavien-Dindo classification were found in 33 (19.8%) patients, whereas grade III and IV complications were treated in 8 (4.8%) patients. One-, 3-, and 5-year survival rates were respectively 78%, 41%, and 37%. Five-year overall survival in patients with colorectal carcinoma after liver resection of metachronous metastases was 48%. We conclude that combined treatment of patients with liver metastases from non-endocrine solid tumours by the multidisciplinary team is safe and effective. A nearly 50% 5-year survival is achievable in a carefully selected group of patients. We also conclude that hepatic resection is an optimal method of surgical treatment of liver metastases. Introduction. Surgical treatment of liver metastases from solid tumours should be provided by multidisciplinary teams. Aim. The aim of the present study is to analyse results of the combined treatment of patients with different solid tumours and liver metastases by single institution multidisciplinary team for last 8 years. Material and methods. This is a retrospective analysis of 166 patients (84 females and 82 males), aged from 19 to 78 years (mean 58 ± 11.2), treated due to liver metastases from solid tumours in various primary localizations: except neuroendocrine tumours. In every patient, perioperative systemic therapy was evaluated in agreement with current recommendations of the Polish Union of Oncology. Results. In the follow-up time available (median 35 months) 46% of patients died. Liver resections were performed in 107 (65%) patients, including 19 patients in whom resections were supplemented with (RF-)thermoablations of their liver metastases. This was the sole surgical treatment in the 59 (36%) patients. Perioperative mortality was 1.2%. Grade II complications according to the Clavien-Dindo classification were found in 33 (19.8%) patients, whereas grade III and IV complications were treated in 8 (4.8%) patients. One-, 3-, and 5-year survival rates were respectively 78%, 41%, and 37%. Five-year overall survival in patients with colorectal carcinoma after liver resection of metachronous metastases was 48%. We conclude that combined treatment of patients with liver metastases from non-endocrine solid tumours by the multidisciplinary team is safe and effective. A nearly 50% 5-year survival is achievable in a carefully selected group of patients. We also conclude that hepatic resection is an optimal method of surgical treatment of liver metastases.
- Open Access
- 14 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 186
Imagine a world without cancer
Since the “War on Cancer” was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type.
- 14 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 186
Open AccessImagine a world without cancer
Since the “War on Cancer” was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type.
- 6 November 2013
- Published by Springer Nature
- p. 119-133
Case Reports
- 6 November 2013
- Published by Springer Nature
- p. 113-118
Intraoperative Radiotherapy with Low-Energy Photons in Rectal Cancer Recurrence
- 6 November 2013
- Published by Springer Nature
- p. 113-118
Intraoperative Radiotherapy with Low-Energy Photons in Rectal Cancer Recurrence
- Open Access
- 1 January 2011
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 6, 411-414
Late outcome after pylorus preserving pancreaticoduodenectomy for ampullary carcinoma following severe acute post-stenting pancreatitis: and review of the literature
Pacjenci poddawani endoskopowej cholangiopankreatografii wstecznej (ECPW) powinni mieć wykonywane protezowanie dróg żółciowych, aby zapobiec zapaleniu dróg żółciowych. Najpoważniejszym jednak powikłaniem po ECPW jest zapalenie trzustki. Dane z piśmiennictwa na temat wpływu zapalenia...
- 1 January 2011
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 6, 411-414
Open AccessLate outcome after pylorus preserving pancreaticoduodenectomy for ampullary carcinoma following severe acute post-stenting pancreatitis: and review of the literature
Pacjenci poddawani endoskopowej cholangiopankreatografii wstecznej (ECPW) powinni mieć wykonywane protezowanie dróg żółciowych, aby zapobiec zapaleniu dróg żółciowych. Najpoważniejszym jednak powikłaniem po ECPW jest zapalenie trzustki. Dane z piśmiennictwa na temat wpływu zapalenia...
Prognostic value of p27kip1 expression in adenocarcinoma of the pancreatic head region
The incidence of pancreatic carcinoma has increased during recent decades, and it is the fourth most common cause of cancer-related mortality [ 1 x [1] Eskelinen, M.J. and Haglund, U.H. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg. 1999; 165: 292–306 Crossref | PubMed | Scopus (41) | Google Scholar See all References , 2 x [2] Silverman, D.T., Schiffman, M., Everhart, J., Goldstein, A., Lillemoe, K.D., and Swanson, G.M. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999; 80: 1830–1837 Crossref | PubMed | Scopus (314) | Google Scholar See all References ]. Early systemic dissemination and local cancer progression are limitations of curative treatment [ 3 x [3] DiMagno, E.P., Reber, H.A., and Tempero, M.A. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999; 117: 1464–1484 Abstract | Full Text | Full Text PDF | PubMed | Scopus (320) | Google Scholar See all References ] [3] . Overall cumulative 5-year survival is extremely poor (0.4–1%), and after curative resection is only 5–15%[ 4 x [4] Bramhall, S.R., Allum, W.H., Jones, A.G., Allwood, A., Cummins, C., and Neoptolemos, J.P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995; 82: 111–115 Crossref | PubMed | Scopus (449) | Google Scholar See all References , 5 x [5] Neoptolemos, J.P., Dunn, J.A., Stocken, D.D., Almond, J., Link, K., and Beger, H. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358: 1576–1585 Abstract | Full Text | Full Text PDF | PubMed | Scopus (681) | Google Scholar See all References , 6 x [6] Yeo, C.J., Sohn, T.A., Cameron, J.L., Hruban, R.H., Lillemoe, K.D., and Pitt, H.A. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg. 1998; 227: 821–831 Crossref | PubMed | Scopus (331) | Google Scholar See all References , 7 x [7] Carr, J.A., Ajlouni, M., Wollner, I., Wong, D., and Velanovich, V. Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival – a ten-year experience. Am Surg. 1999; 65: 1143–1149 PubMed | Google Scholar See all References ]. Pathological stage, histological differentiation, localization of the tumour and involved margins are known prognostic factors [ 8 x [8] Geer, R.J. and Brennan, M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165: 68–72 Abstract | Full Text PDF | PubMed | Scopus (682) | Google Scholar See all References , 9 x [9] Fortner, J.G., Klimstra, D.S., Senie, R.T., and Maclean, B.J. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 1996; 223: 147–153 Crossref | PubMed | Scopus (213) | Google Scholar See all References , 10 x [10] Magistrelli, P., Antinori, A., Crucitti, A., La Greca, A., Masetti, R., and Coppola, R. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol. 2000; 74: 36–40 Crossref | PubMed | Scopus (65) | Google Scholar See all References , 11 x [11] Lundin, J., Nordling, S., von Boguslawsky, K., Roberts, P.J., and Haglund, C. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res. 1995; 15: 2659–2668 PubMed | Google Scholar See all References , 12 x [12] Luttges, J., Schemm, S., Vogel, I., Hedderich, J., Kremer, B., and Kloppel, G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000; 191: 154–161 Crossref | PubMed | Scopus (103) | Google Scholar See all References , 13 x [13] Takahashi, T., Niino, N., Ishikura, H., Okushiba, S., Dohke, M., and Katoh, H. Predictive factors for long-term survival in patients with pancreatic carcinoma. Hepatogastroenterology. 1997; 44: 1463–1468 PubMed | Google Scholar See all References ].
Prognostic value of p27kip1 expression in adenocarcinoma of the pancreatic head region
The incidence of pancreatic carcinoma has increased during recent decades, and it is the fourth most common cause of cancer-related mortality [ 1 x [1] Eskelinen, M.J. and Haglund, U.H. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg. 1999; 165: 292–306 Crossref | PubMed | Scopus (41) | Google Scholar See all References , 2 x [2] Silverman, D.T., Schiffman, M., Everhart, J., Goldstein, A., Lillemoe, K.D., and Swanson, G.M. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999; 80: 1830–1837 Crossref | PubMed | Scopus (314) | Google Scholar See all References ]. Early systemic dissemination and local cancer progression are limitations of curative treatment [ 3 x [3] DiMagno, E.P., Reber, H.A., and Tempero, M.A. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999; 117: 1464–1484 Abstract | Full Text | Full Text PDF | PubMed | Scopus (320) | Google Scholar See all References ] [3] . Overall cumulative 5-year survival is extremely poor (0.4–1%), and after curative resection is only 5–15%[ 4 x [4] Bramhall, S.R., Allum, W.H., Jones, A.G., Allwood, A., Cummins, C., and Neoptolemos, J.P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995; 82: 111–115 Crossref | PubMed | Scopus (449) | Google Scholar See all References , 5 x [5] Neoptolemos, J.P., Dunn, J.A., Stocken, D.D., Almond, J., Link, K., and Beger, H. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358: 1576–1585 Abstract | Full Text | Full Text PDF | PubMed | Scopus (681) | Google Scholar See all References , 6 x [6] Yeo, C.J., Sohn, T.A., Cameron, J.L., Hruban, R.H., Lillemoe, K.D., and Pitt, H.A. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg. 1998; 227: 821–831 Crossref | PubMed | Scopus (331) | Google Scholar See all References , 7 x [7] Carr, J.A., Ajlouni, M., Wollner, I., Wong, D., and Velanovich, V. Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival – a ten-year experience. Am Surg. 1999; 65: 1143–1149 PubMed | Google Scholar See all References ]. Pathological stage, histological differentiation, localization of the tumour and involved margins are known prognostic factors [ 8 x [8] Geer, R.J. and Brennan, M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165: 68–72 Abstract | Full Text PDF | PubMed | Scopus (682) | Google Scholar See all References , 9 x [9] Fortner, J.G., Klimstra, D.S., Senie, R.T., and Maclean, B.J. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 1996; 223: 147–153 Crossref | PubMed | Scopus (213) | Google Scholar See all References , 10 x [10] Magistrelli, P., Antinori, A., Crucitti, A., La Greca, A., Masetti, R., and Coppola, R. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol. 2000; 74: 36–40 Crossref | PubMed | Scopus (65) | Google Scholar See all References , 11 x [11] Lundin, J., Nordling, S., von Boguslawsky, K., Roberts, P.J., and Haglund, C. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res. 1995; 15: 2659–2668 PubMed | Google Scholar See all References , 12 x [12] Luttges, J., Schemm, S., Vogel, I., Hedderich, J., Kremer, B., and Kloppel, G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000; 191: 154–161 Crossref | PubMed | Scopus (103) | Google Scholar See all References , 13 x [13] Takahashi, T., Niino, N., Ishikura, H., Okushiba, S., Dohke, M., and Katoh, H. Predictive factors for long-term survival in patients with pancreatic carcinoma. Hepatogastroenterology. 1997; 44: 1463–1468 PubMed | Google Scholar See all References ].